ReviewLeukemia2013
The hunting of targets: challenge in miRNA research.
Review in Leukemia, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Meta-analysis of Hsa-mir-499 polymorphism (rs3746444) for cancer risk: evidence from 31 case-control studies.BMC medical genetics · 2014Pooled it
- Repression of miR-29 via MYC leads to increased CD40 signaling in transformed follicular lymphoma.Leukemia · 2026Trial
- Ferroptosis inhibitors: past, present and future.Frontiers in pharmacology · 2024Review
- Expression study of microRNA cluster on chromosome 19 (C19MC) in tumor tissue and serum of breast cancer patient.Molecular biology reports · 2023Article
- The role of miRNAs in Behçet's disease.Frontiers in immunology · 2023Review
- Association of Circular RNA and Long Non-Coding RNA Dysregulation with the Clinical Response to Immune Checkpoint Blockade in Cutaneous Metastatic Melanoma.Biomedicines · 2022Article
- shRNAs targeting mouse Adam10 diminish cell response to proinflammatory stimuli independently of Adam10 silencing.Biology open · 2022Article
- Integrative approaches for studying the role of noncoding RNAs in influencing drug efficacy and toxicity.Expert opinion on drug metabolism & toxicology · 2022Article
- Non-targeting control for MISSION shRNA library silencesMolecular therapy. Nucleic acids · 2021Article
- Article
- Circular RNA circCSPP1 knockdown attenuates doxorubicin resistance and suppresses tumor progression of colorectal cancer via miR-944/FZD7 axis.Cancer cell international · 2021Article
- Expression Profile of Circulating MicroRNAs in Dogs With Cardiac Hypertrophy: A Pilot Study.Frontiers in veterinary science · 2021Article
- Regulatory Mechanisms of Epigenetic miRNA Relationships in Human Cancer and Potential as Therapeutic Targets.Cancers · 2020Review
- Genome-wide computational prediction of miRNAs in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) revealed target genes involved in pulmonary vasculature and antiviral innate immunity.Molecular biology research communications · 2020Article
- MicroRNA: Another Pharmacological Avenue for Colorectal Cancer?Frontiers in cell and developmental biology · 2020Review
- Ectopic expression of miR-944 impairs colorectal cancer cell proliferation and invasion by targeting GATA binding protein 6.Journal of cellular and molecular medicine · 2019Article
- The Modulatory Role of MicroRNA-873 in the Progression of KRAS-Driven Cancers.Molecular therapy. Nucleic acids · 2019Article
- Computational prediction of miRNAs in Nipah virus genome reveals possible interaction with human genes involved in encephalitis.Molecular biology research communications · 2018Article
- miR‑1 inhibits the progression of colon cancer by regulating the expression of vascular endothelial growth factor.Oncology reports · 2018Article
- Expression of microRNA-155 in inflammatory cells modulates liver injury.Hepatology (Baltimore, Md.) · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNAs (miRNAs) are small noncoding RNAs that control the expression of around 60% of the human protein-coding genes. In the past decade, deregulation of miRNAs (by expression and/or function) has been associated with the pathogenesis, progression and prognosis of different diseases, including leukemia. The number of discovered genes encoding miRNAs has risen exponentially in this period, but the numbers of miRNA-target genes discovered and validated lag far behind. Scientists have gained more in-depth knowledge of the basic mechanism of action of miRNAs, but the main challenge still remaining is the identification of direct targets of these important 'micro-players', to understand how they fine-tune so many biological processes in both healthy and diseased tissue. Many technologies have been developed in the past few years, some with more potential than others, but all with their own pros and cons. Here, we review the most common and most potent computational and experimental approaches for miRNA-target gene discovery and discuss how the hunting of targets is challenging but possible by taking the experimental limitations in consideration and choosing the correct cellular context for identifying relevant target genes.
Indexed as
Identifiers
22836911What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.